| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Prepaid expenses and other current assets | 448 | |||
| Incentive and tax receivables | 820 | |||
| Cash and cash equivalents | 101,164 | |||
| Total assets | 102,432 | |||
| Accrued liabilities - note 3 | 3,929 | |||
| Deferred grant income - note 4 | 805 | |||
| Accounts payable | 6,740 | |||
| Total liabilities | 11,474 | |||
| Accumulated deficit | -372,621 | |||
| Capital stock authorized10,000,000 preferred stock, par value 0.001 per share | 0 | |||
| Capital stock authorized200,000,000 common stock, par value 0.001 per share 84,985,449 common shares (september 30, 2024 - 84,795,517) | 85 | |||
| Additional paid-in capital | 463,494 | |||
| Total stockholders equity | 90,958 | |||
| Total liabilities and stockholders equity | 102,432 | |||
ANAVEX LIFE SCIENCES CORP. (AVXL)
ANAVEX LIFE SCIENCES CORP. (AVXL)